PE20221918A1 - 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 - Google Patents

3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52

Info

Publication number
PE20221918A1
PE20221918A1 PE2022002146A PE2022002146A PE20221918A1 PE 20221918 A1 PE20221918 A1 PE 20221918A1 PE 2022002146 A PE2022002146 A PE 2022002146A PE 2022002146 A PE2022002146 A PE 2022002146A PE 20221918 A1 PE20221918 A1 PE 20221918A1
Authority
PE
Peru
Prior art keywords
group
pyrazines
gpr52
phenoxiazetidin
substituted
Prior art date
Application number
PE2022002146A
Other languages
English (en)
Spanish (es)
Inventor
Kai Gerlach
Barbara Bertani
Marco Ferrara
Giacomo Fossati
Scott Hobson
Uta Friederike Lessel
Frank Runge
Graeme Semple
Ursula Mueller-Vieira
Julian Wippich
Yifeng Xiong
Original Assignee
Boehringer Ingelheim Int
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Arena Pharm Inc filed Critical Boehringer Ingelheim Int
Publication of PE20221918A1 publication Critical patent/PE20221918A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2022002146A 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52 PE20221918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063001640P 2020-03-30 2020-03-30
PCT/EP2021/058099 WO2021198149A1 (en) 2020-03-30 2021-03-29 Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity

Publications (1)

Publication Number Publication Date
PE20221918A1 true PE20221918A1 (es) 2022-12-29

Family

ID=75362607

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002146A PE20221918A1 (es) 2020-03-30 2021-03-29 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52

Country Status (20)

Country Link
US (1) US11780827B2 (https=)
EP (1) EP4126850B1 (https=)
JP (1) JP7617134B2 (https=)
KR (1) KR20220161454A (https=)
CN (1) CN115697997B (https=)
AR (1) AR121675A1 (https=)
AU (1) AU2021250303A1 (https=)
BR (1) BR112022018996A2 (https=)
CA (1) CA3176265A1 (https=)
CO (1) CO2022014886A2 (https=)
CR (1) CR20220554A (https=)
DO (1) DOP2022000203A (https=)
EC (1) ECSP22080683A (https=)
IL (1) IL296823A (https=)
JO (1) JOP20220235A1 (https=)
MX (1) MX2022012067A (https=)
PE (1) PE20221918A1 (https=)
PH (1) PH12022552553A1 (https=)
TW (1) TW202204343A (https=)
WO (1) WO2021198149A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206413A (zh) 2020-04-22 2022-02-16 美商紐羅克里生物科學有限公司 Gpr52調節劑及其使用方法
US12115157B2 (en) 2021-09-14 2024-10-15 Boehringer Ingelheim International Gmbh 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament
CN119143731B (zh) * 2024-09-13 2025-08-26 中国海洋大学 一种吡嗪酰胺类化合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2055500A (en) * 1998-12-23 2000-07-31 Eli Lilly And Company Aromatic amides
WO2009107391A1 (ja) 2008-02-27 2009-09-03 武田薬品工業株式会社 6員芳香環含有化合物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
JPWO2009157196A1 (ja) 2008-06-25 2011-12-08 武田薬品工業株式会社 アミド化合物
WO2011078360A1 (ja) * 2009-12-24 2011-06-30 武田薬品工業株式会社 アミド化合物
EP2530078A1 (en) * 2010-01-27 2012-12-05 Takeda Pharmaceutical Company Limited Thiazole derivative
WO2011145735A1 (ja) * 2010-05-21 2011-11-24 武田薬品工業株式会社 チアゾール誘導体
WO2012020738A1 (ja) * 2010-08-09 2012-02-16 武田薬品工業株式会社 複素環化合物およびその用途
WO2012076063A1 (en) * 2010-12-10 2012-06-14 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
KR20180004193A (ko) * 2015-04-29 2018-01-10 아레나 파마슈티칼스, 인크. Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드
AU2016324317A1 (en) * 2015-09-17 2018-03-08 Coda Biotherapeutics, Inc. Compositions and methods for treating neurological disorders

Also Published As

Publication number Publication date
CA3176265A1 (en) 2021-10-07
EP4126850B1 (en) 2024-04-17
CN115697997A (zh) 2023-02-03
PH12022552553A1 (en) 2024-01-03
MX2022012067A (es) 2022-10-13
DOP2022000203A (es) 2022-11-30
IL296823A (en) 2022-11-01
US20220356172A1 (en) 2022-11-10
JP7617134B2 (ja) 2025-01-17
CR20220554A (es) 2023-01-09
KR20220161454A (ko) 2022-12-06
WO2021198149A1 (en) 2021-10-07
JOP20220235A1 (ar) 2022-09-28
US11780827B2 (en) 2023-10-10
EP4126850A1 (en) 2023-02-08
AU2021250303A1 (en) 2022-09-22
BR112022018996A2 (pt) 2022-11-01
CO2022014886A2 (es) 2022-10-31
ECSP22080683A (es) 2022-11-30
AR121675A1 (es) 2022-06-29
CN115697997B (zh) 2024-07-30
TW202204343A (zh) 2022-02-01
JP2023522307A (ja) 2023-05-30

Similar Documents

Publication Publication Date Title
PE20221918A1 (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas que tienen actividad agonista de gpr52
CL2020000029A1 (es) Nuevos compuestos de carboxamida sulfonamida.
CL2020000367A1 (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
PE20210050A1 (es) Nuevos compuestos de sulfonamida carboxamida
AR108262A1 (es) Derivados de piridiniltriazol sustituidos con amida y usos de estos
AR029215A1 (es) Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti
MX2021006754A (es) Derivados de quinoleina para el tratamiento de enfermedades inflamatorias.
PE20200340A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
PE20200604A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2022011388A2 (es) Inhibidores heterocíclicos de pad4
MX385276B (es) Tratamiento para la enfermedad de parkinson
PE20212070A1 (es) Moduladores de trex1
PE20252542A1 (es) Compuestos derivados de 2-(3-piridinil)-2h-indazol-4-carboxamidas con actividad pesticida
PE20231308A1 (es) Proceso e intermedios para preparar un inhibidor de jak1
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
MX2022011333A (es) Compuestos moduladores de gpr52.
PE20241188A1 (es) Agonistas de rxfp1
EA200600878A1 (ru) Производные феноксиуксусных кислот, применимые в качестве двойных агонистов активируемого пероксисомным пролифератором рецептора ( ppar )
PY2085970A (es) Compuestos químicos
CY1119809T1 (el) Μυκητοκτονος συνθεση και μεθοδος για την καταπολεμηση φυτικης ασθενειας
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer